Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard F Pollock

Showing results (1-10 of 86) with videos related to

Pageof 9
Sort By:
Clinicoeconomics and Outcomes Research : CEOR|January 14, 2021
An Economic Analysis of Ferric Derisomaltose versus Ferric Carboxymaltose in the Treatment of Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease in Norway, Sweden, and FinlandRichard F Pollock, Gorden Muduma
Clinicoeconomics and Outcomes Research : CEOR|August 30, 2017
A budget impact analysis of parenteral iron treatments for iron deficiency anemia in the UK: reduced resource utilization with iron isomaltoside 1000Richard F Pollock, Gorden Muduma
Expert Review of Hematology|January 14, 2020
Indirect methods of comparison of the safety of ferric derisomaltose, iron sucrose and ferric carboxymaltose in the treatment of iron deficiency anemiaRichard F Pollock, Patrick Biggar
Expert Review of Hematology|January 29, 2019
A systematic literature review and indirect comparison of iron isomaltoside and ferric carboxymaltose in iron deficiency anemia after failure or intolerance of oral iron treatmentRichard F Pollock, Gorden Muduma
BMC Bioinformatics|March 28, 2008
BioSAVE: display of scored annotation within a sequence contextRichard F Pollock, Boris Adryan
Journal of Medical Economics|March 26, 2020
A patient-level cost-effectiveness analysis of iron isomaltoside versus ferric carboxymaltose for the treatment of iron deficiency anemia in the United KingdomRichard F Pollock, Gorden Muduma
Advances in Therapy|November 21, 2018
An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in DenmarkRichard F Pollock, Gorden Muduma
Clinicoeconomics and Outcomes Research : CEOR|April 26, 2018
An evaluation of the budget impact of a new 20% subcutaneous immunoglobulin (Ig20Gly) for the management of primary immunodeficiency diseases in SwitzerlandRichard F Pollock, Lisa M Meckley
Advances in Therapy|February 8, 2020
Development of a Resource Impact Model for Clinics Treating Pre-Operative Iron Deficiency Anemia in IrelandFrank Loughnane, Gorden Muduma, Richard F Pollock
Journal of Medical Economics|April 24, 2014
A UK analysis of the cost of switching renal transplant patients from an immediate-release to a prolonged-release formulation of tacrolimus based on differences in trough concentration variabilityGorden Muduma, Isaac Odeyemi, Richard F Pollock
Pageof 9

Showing results (1-10 of 86) with videos related to

Sort By:
Pageof 9
Clinicoeconomics and Outcomes Research : CEOR|January 14, 2021
An Economic Analysis of Ferric Derisomaltose versus Ferric Carboxymaltose in the Treatment of Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease in Norway, Sweden, and FinlandRichard F Pollock, Gorden Muduma
Clinicoeconomics and Outcomes Research : CEOR|August 30, 2017
A budget impact analysis of parenteral iron treatments for iron deficiency anemia in the UK: reduced resource utilization with iron isomaltoside 1000Richard F Pollock, Gorden Muduma
Expert Review of Hematology|January 14, 2020
Indirect methods of comparison of the safety of ferric derisomaltose, iron sucrose and ferric carboxymaltose in the treatment of iron deficiency anemiaRichard F Pollock, Patrick Biggar
Expert Review of Hematology|January 29, 2019
A systematic literature review and indirect comparison of iron isomaltoside and ferric carboxymaltose in iron deficiency anemia after failure or intolerance of oral iron treatmentRichard F Pollock, Gorden Muduma
BMC Bioinformatics|March 28, 2008
BioSAVE: display of scored annotation within a sequence contextRichard F Pollock, Boris Adryan
Journal of Medical Economics|March 26, 2020
A patient-level cost-effectiveness analysis of iron isomaltoside versus ferric carboxymaltose for the treatment of iron deficiency anemia in the United KingdomRichard F Pollock, Gorden Muduma
Advances in Therapy|November 21, 2018
An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in DenmarkRichard F Pollock, Gorden Muduma
Clinicoeconomics and Outcomes Research : CEOR|April 26, 2018
An evaluation of the budget impact of a new 20% subcutaneous immunoglobulin (Ig20Gly) for the management of primary immunodeficiency diseases in SwitzerlandRichard F Pollock, Lisa M Meckley
Advances in Therapy|February 8, 2020
Development of a Resource Impact Model for Clinics Treating Pre-Operative Iron Deficiency Anemia in IrelandFrank Loughnane, Gorden Muduma, Richard F Pollock
Journal of Medical Economics|April 24, 2014
A UK analysis of the cost of switching renal transplant patients from an immediate-release to a prolonged-release formulation of tacrolimus based on differences in trough concentration variabilityGorden Muduma, Isaac Odeyemi, Richard F Pollock
Pageof 9